cadno Friday, 10/13/17 05:26:58 AM Re: blu_1 post# 124407 0 Post # of 145333 Quote:Are you talking about 10mg of dzp or 5mg, prolly just 10mg, so you're cherry picking the 10mg group. For 273 you're not just cherry picking the 50mg group, you're assessing performance of all scores and comparing that to 10mg dzp group. You looking at 57 weeks or 52 weeks on dzp? 273 was on upward trend beyond 52 weeks on all measures (mmse, adcs adl, erp, adas cog). That so with dzp? Also, In the 273 trial, those patients were getting no benefit and no synergy from dzp b/c the patients had been on dzp long term before trial start date. We know dzp doesn't do jack after 6 mos. So dzp w/superior sigma affinity was probably just blocking 273 from docking onto sigma receptors and not contributing a benefit. I'm comparing to the charts I found, which I believe are optimized dosage. I would compare to an optimized dosage for 2-73, but that isn't available. There is just the MMSE chart for all patients. I'm looking at the whole thing. I don't put that much statistically into that uptick after 52 weeks. People seem to be putting a lot into changes of less than a point on the MMSE, and with a small sample size at that. To me, the overall picture from the 2-73 MMSE chart, within the small range on the MMSE it is operating, is that it is fairly stable over 12 months. The same for donepezil. As rubyred pointed out, it does decline (like 2-73) after a month or couple months. But we're talking about movement within about 2 points on the MMSE over 12 months, and a small fraction of 1 point over each 4 weeks. It's all small movements. But when looking over more than 12 months you really do see that the decline is exacerbated and continues unfettered, which is why I want to see the chart for 2-73 over a longer period as well. Preferably, of course, with dose optimized for a true comparison. I don't know about the dzp affecting 2-73. There's not enough data. Does it even say how many patients were on both 2-73 and dzp versus just 2-73?